SMU127 is an agonist of the Toll-like receptor 1/2 (TLR1/2) heterodimer; it induces NF-κB signaling in cells expressing human TLR2 (EC50 = 0.55 µM) without activating cells expressing human TLR3, -4, -5, -7, or -8 at concentrations ranging from 0.1 to 100 µM; it stimulates TNF-α production in isolated human peripheral blood mononuclear cells (PBMCs) at concentrations of 0.01 to 1 µM; in vivo, SMU127 (0.1 mg per animal) reduces tumor volume in the 4T1 murine breast cancer model.